HomeClinics HomeAbout ClinicsAll ClinicsHot TopicsAdvancesSpecial OffersCME
Logo
Search for

Volume 24, Issue 4, Pages 727-738 (November 2004)


View previous. 12 of 16 View next.

Genetically modified allergens

Verena Niederberger, MDaCorresponding Author Informationemail address, Rudolf Valenta, MDb

For more than 90 years, allergen-specific immunotherapy, the only causative allergy treatment, has remained basically unchanged. The development of molecular biology techniques has led to the preparation of individual recombinant allergens from the most important allergen sources. Recombinant allergens can be used to determine the individual sensitization profile of allergic patients and have allowed the development of novel therapeutic tools. This article summarizes data on genetically modified recombinant allergen derivatives with reduced allergenic activity, which may be used to improve the safety and efficacy of specific immunotherapy.

a Department of Otorhinolaryngology, Vienna General Hospital, Medical University of Vienna, Ebene 8J, Waehringer Guertel 18-20, Vienna A-1090, Austria

b Department of Pathophysiology, Vienna General Hospital, Medical University of Vienna, Ebene 8J, Waehringer Guertel 18-20, Vienna A-1090, Austria

Corresponding Author InformationCorresponding author

 This article was supported by the CeMM project of the Austrian Academy of Sciences and by projects F01801 and F01811 of the Austrian Science Fund.

PII: S0889-8561(04)00084-0

doi:10.1016/j.iac.2004.06.009


View previous. 12 of 16 View next.